Key Takeaways KROS surged 85.6% in the past year, beating its industry and sector after announcing a review.Keros Therapeutics advanced KER-065 for DMD, reported phase I results and gained FDA orphan status.KROS partnered with Takeda on elritercept, started a phase III study and received a $10M milestone.Keros Therapeutics (KROS) has put a strong performance in the past year. Shares of the company have skyrocketed 85.6% in this time frame compared with the industry’s gain of 18.8%. The stock has also outper ...